New study aims to uncover hidden cancer clues in autoimmune disease

NCT ID NCT06808672

Ongoing Knowledge-focused Sponsor: Azienda USL Reggio Emilia - IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines blood samples from 50 people with dermatomyositis, an autoimmune disease that raises the risk of cancer. Researchers are looking for new antibodies and immune molecules that might signal which patients are more likely to develop cancer. The goal is to improve cancer screening for these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could lead to a blood test that helps doctors identify which dermatomyositis patients need cancer screening.
What could go wrong: This is an early-stage observational study with only 50 participants. The findings may not lead to a practical test, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dermatomyositis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATOMYOSITIS

Contacts and locations

Locations

AUSL-IRCCS di Reggio Emilia

Reggio Emilia, 42122, Italy
Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari

Bari, 70124, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.